SEC Form 3 · accession 0001209191-19-003281

UroGen Pharma Ltd. · URGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jan 1, 2019

Accepted (ET)

Jan 10, 2019 · 5:08 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001668243

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Ordinary Shares	holding	—	—		—	84,211	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F1	$5.00	holding	—	—	—	—	Sep 1, 2022	Ordinary Shares	3,241	—	D
Stock Option (right to buy)^F2	$4.02	holding	—	—	—	—	Oct 14, 2019	Ordinary Shares	128,000	—	D
Stock Option (right to buy)^F1	$5.00	holding	—	—	—	—	Jul 27, 2021	Ordinary Shares	3,241	—	D
Stock Option (right to buy)^F3	$5.00	holding	—	—	—	—	Oct 7, 2022	Ordinary Shares	160,000	—	D
Stock Option (right to buy)^F4	$43.67	holding	—	—	—	—	Jan 10, 2028	Ordinary Shares	20,000	—	D
Stock Option (right to buy)^F5	$59.23	holding	—	—	—	—	Jun 4, 2028	Ordinary Shares	10,000	—	D

F1Fully vested.
F225% of the shares underlying the stock option vested on each of October 13, 2012, October 13, 2013, October 13, 2014 and October 13, 2015.
F325% of the shares underlying the stock option vested on each of October 7, 2016, October 7, 2017 and October 7, 2018 and the remaining 25% of the shares will vest on October 7, 2019.
F425% of the shares underlying the stock option vested on each of April 10, 2018, July 10, 2018 and October 10, 2018 and the remaining 25% of the shares will vest on January 10, 2019.
F525% of the shares underlying the stock option vested on each of September 4, 2018 and December 4, 2018 and the remaining shares will vest 25% on each of March 4, 2019 and June 4, 2019.

Exhibit List - Exhibit 24 - Power of Attorney